Chelsea Therapeutics (NASDAQ: CHTP) left investors stunned today after taking a steep tumble. Shares dropped almost 30% after the Food and Drug Administration (FDA) posted briefing documents ahead of an advisory committee meeting for Chelsea's drug Northera. The meeting is scheduled for next week, but what did the market see in today's release? Analysts David Williamson and Max Macaluso discuss the details in the video below.
You're reading a free article with opinions that may differ from The Motley Fool's Premium Investing Services. Become a Motley Fool member today to get instant access to our top analyst recommendations, in-depth research, investing resources, and more. Learn More
Down 29%: Why Chelsea Therapeutics International Ltd. Shares Crashed Today
Why did Chelsea Therapeutics shares tumble today?
David Williamson has no position in any stocks mentioned. Max Macaluso, Ph.D. has no position in any stocks mentioned. The Motley Fool has no position in any of the stocks mentioned. We Fools may not all hold the same opinions, but we all believe that considering a diverse range of insights makes us better investors. The Motley Fool has a disclosure policy.
Related Articles





Premium Investing Services
Invest better with The Motley Fool. Get stock recommendations, portfolio guidance, and more from The Motley Fool's premium services.